Is it true that chemotherapy can damage my heart?

 

Ask a Question 

Q: Is it true that chemotherapy can damage my heart? 

A: Some chemotherapy drugs may damage heart muscles. This can lead to problems that may appear shortly after treatment or years later. Some damage is mild and detectable only through testing; other may be severe, resulting in conditions such as congestive heart failure. Limiting the cumulative dose of heart-damaging drugs helps prevent cardiac problems, as does giving smaller doses more frequently or taking an additional drug specially formulated to reduce damage.

Talk with your doctor about any possible cardiac effects from the medication you are being given. If you are to receive a chemotherapy drug that has the possibility of weakening the heart muscle, a baseline measurement of your heart function will be ordered through an echocardiogram or MUGA scan. These are noninvasive tests that can be performed at your hospital outpatient department or in a cardiologist's office.
--Bernice Crook, RN, OCN

Learn more about cardiac problems and other long-term side effects from treatment.

Latest Cancer News
Avastin® Linked with Increased Risk of Blood Clots

November 20, 2008 — According to a combined analysis of previously published studies, cancer patients who use Avastin® (bevacizumab) may have an increased risk of venous thromboembolism (a blood clot in a vein). These results were published in the Journal of the American Medical Association.

Addition of Avastin® to Paraplatin®, Taxol®, and Erbitux® Promising for Advanced NSCLC

November 20, 2008 — Researchers affiliated with the Southwest Oncology Group have reported that the four-drug combination of chemotherapy agents Paraplatin® (carboplatin) and Taxol® (paclitaxel) plus targeted therapies Avastin® (bevacizumab) and Erbitux® (cetuximab) is safe and may improve survival in patients with advanced non–small cell lung cancer (NSCLC). The details of this study were presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology November 13-15.

Avastin® Increases Risk of Venous Thromboembolism

November 20, 2008 — Researchers from Stony Brook University have reported that the use of Avastin® (bevacizumab) increases the risk of thromboembolism. The details of this review were published in the November 19, 2008 issue of the Journal of the American Medical Association.

Select news items provided by Reuters Health